Can someone help me understand exactly what Dr JL
Post# of 157598

[00:30:10]: In the meantime we've started to enroll our Colorectal cancer study have a bunch of sites actively enrolling now and what we're going to be doing shortly is submitting a request to the FDA for a meeting at which point we're going to give them a rollover protocol for the Colorectal cancer patients that we're monitoring their PD-L1 status during the study and in the rollover protocol. We hope to then provide them a checkpoint inhibitor to see if we can replicate that clinical benefit, that survival benefit that we saw in the breast cancer patients.

